Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

List, James F., Whaley, Jean M.·2011·Kidney International

DOI 10.1038/ki.2010.512

Cited by (183)

Items 101–183 of 183

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku · 2019 · Journal of Diabetes Investigation
Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on P hase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述
GEORGE E. DAILEY · 2015 · Journal of Diabetes
In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
Toshiki Tsuboi, Keita Hattori, Takuji Ishimoto, Kentaro Imai, Tomohito Doke, Junichiro Hagita, Jumpei Ariyoshi, Kazuhiro Furuhashi, Noritoshi Kato, Yasuhiko Ito et al. · 2024 · Molecular Therapy — Nucleic Acids
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus
Bianca Hemmingsen, Jesper Krogh, Maria‐Inti Metzendorf, Bernd Richter · 2016 · Cochrane Database of Systematic Reviews
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
Usama A. Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim · 2021 · Nefrología
Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
Toshimi Imai, Tetsu Akimoto, Chiharu Ito, Takahiro Masuda, Daisuke Nagata · 2015 · Drug Target Insights
Ameliorative effect of polydatin on hyperglycemia and renal injury in streptozotocin-induced diabetic rats
Lijuan Wang, Liji Huang, Nan Li, Junjun Miao, Wei Liu, Jiangyi Yu · 2019 · Cellular and Molecular Biology
Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes
Alan J. Garber · 2015 · Endocrine Practice
Adverse Liver and Renal Outcomes After Initiating SGLT ‐2i and GLP ‐ 1RA Therapy Among Patients With Diabetes and MASLD
Arunkumar Krishnan, Carolin Victoria Schneider, Diptasree Mukherjee, Tinsay A. Woreta, Saleh A. Alqahtani · 2025 · Journal of Diabetes
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku · 2020 · Journal of Diabetes Investigation
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai · 2025 · Frontiers in Cardiovascular Medicine
Repurposing metabolic drugs as anti-inflammatory agents
Andrew E. Hogan, Cian Davis, Benjamin Jenkins, Nicholas Jones, Donal Brendan O'Shea · 2025 · Trends in Endocrinology and Metabolism
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
Hamideh Asadinejad, Soroush Taherkhani, Sakine Mosaei Golboos, Yaser Azizi, Ali Mohammadkhanizadeh · 2025 · Molecular Neurobiology
Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J‐ STEP / EL ): A 12‐week interim analysis
Kazunori Utsunomiya, Naoki Shimmoto, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Hiroyuki Kameda, Masahiro Tamura, Hanako Mihara, Kohei Kaku · 2016 · Journal of Diabetes Investigation
Sodium–glucose cotransporter 2 inhibitors in horses—Magic bullet or latest fad?
Tania Sundra, Guy D. Lester, Gabriele Rossi, David I. Rendle · 2023 · Equine Veterinary Journal
Circulating complement‐1q tumor necrosis factor‐α‐related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin
Cheng Zhang, Yong Luo, Rui Liu, Xiaoqiang Li, Mengliu Yang, Yu Zhang, Ling Li, Huaming Mou, Lian Guo, Jing Li et al. · 2019 · Journal of Diabetes Investigation
Toxicology of Medications for Diabetes Mellitus
Kevin T. Baumgartner, Jason M. Devgun · 2021 · Critical Care Clinics
Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers
Scott E. Schaeffer, Carol DesLauriers, Henry A. Spiller, Alfred Aleguas, Salvador Baeza, Mark L. Ryan · 2017 · Clinical Toxicology
A practical approach to hyperinsulinaemia in horses with equine metabolic syndrome
Tania Sundra, Gabriele Rossi, David I. Rendle, Guy D. Lester · 2024 · Equine Veterinary Education
Sodium-glucose cotransporter 2 inhibitors and cardiorenal outcomes in kidney transplantation
Gauranga Mahalwar, Roy O. Mathew, Janani Rangaswami · 2023 · Current Opinion in Nephrology & Hypertension
Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia‐associated laminitis
Tania Sundra, Erin A. Kelty, Gabriele Rossi, Guy D. Lester, David I. Rendle · 2024 · Equine Veterinary Education
New avenues for the pharmacological management of type 2 diabetes: An update
Thomas Cuny, Bruno Guerci, Bertrand Cariou · 2012 · Annales d Endocrinologie
Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Ching-Lun Chien, Yen‐Chou Chen, Daniel C. Malone, Yueh-Lung Peng, Yu Ko · 2020 · Current Medical Research and Opinion
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Jaime A. Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed, Zanariah Binti Hussein · 2022 · Journal of Diabetes Investigation
Pharmacological Treatments for Type 2 Diabetes
Roberto Pontarolo, Andréia Cristina Conegero Sanches, Astrid Wiens, Cássio Marques Perlin, Fernanda S. Tonin, Helena Hiemisch Lobo Borba, Luana Lenzi, Suelem Tavares da Silva Penteado · 2015 · InTech eBooks
A review of recent developments in the pharmacological prevention and treatment of endocrinopathic laminitis
Melody Anne de Laat, Martin N. Sillence · 2020 · Animal Production Science
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study
Yujin Shin, Haeri Choi, Soo Kyung Lim · 2021 · Diabetes Research and Clinical Practice
Mode of action and human relevance assessment of male CD‐1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin
Jonathan A. Phillips, Mitchell E. Taub, Matthew S. Bogdanffy, Jing Yuan, Brian Knight, James D. Smith, Warren W. Ku · 2022 · Journal of Applied Toxicology
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
Usama A. Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim · 2022 · Nefrología (English Edition)
Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
Rune E. Kuhre, Carolyn Fiona Deacon, Nicolai J. Wewer Albrechtsen, Jens Juul Holst · 2021 · Diabetes Obesity and Metabolism
Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes
Shivani Sharma, Amit Mittal, Shubham Kumar, Anu Mittal · 2021 · Current Diabetes Reviews
Design, Syntheses, and SAR Studies of Carbocyclic Analogues of Sergliflozin as Potent Sodium‐Dependent Glucose Cotransporter 2 Inhibitors
Tony K. M. Shing, Wai‐Lung Ng, Judy Yuet‐Wa Chan, Clara Bik‐San Lau · 2013 · Angewandte Chemie
The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease
Xinhui Feng, Yuqi Zheng, Haochen Guan, Xun Clare Zhou, Ying Xu, Xiaoli Zhang, Chensheng Fu, Jing Xiao, Zhibin Ye · 2020 · Endocrine Research
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2, in patients with chronic kidney disease: A randomized trial
Yanling He, Alok S. Pachori, Ping Chen, Shenglin Ma, Anisha E. Mendonza, Ahmed Amer, Thomas C Marbury, Markus Hinder · 2021 · Diabetes Obesity and Metabolism
SGLT2 inhibitors and AMPK crosstalk in diabetes mellitus: mechanistic insights and therapeutic applications
Kiavash Hushmandi, Navvabeh Salarizadeh, Behzad Einollahi, Morteza Izadi, Pardis Doosti, Mohammad Javad Behzadnia, William C. Cho, Tooba Yousefi, Seyedeh Mahdieh Khoshnazar, Mina Alimohammadi et al. · 2026 · Journal of Diabetes & Metabolic Disorders
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Alexander Kühn, Jean Park, Adline Ghazi, Vanita R. Aroda · 2017 · Current Cardiology Reports
Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis
Xuesong Zhang, Ying Zhang, Yuanhui Hu · 2022 · Frontiers in Cardiovascular Medicine
Design, Synthesis and in vivo Evaluation of Novel C‐Aryl Glucosides as Potent Sodium‐Dependent Glucose Cotransporters Inhibitors for the Treatment of Diabetes
Zheng Li, Xuekun Wang, Xue Jun Xu, Qianqian Qiu, Lei Jiao, Wenlong Huang, Hai Qian · 2015 · Chemical Biology & Drug Design
A novel SGLT2 inhibitor, SU-011, improves glycaemic control in rodents without the risk of hypoglycaemia and weight gain
Fei Huang, Fuwei Dai, Jianhua Bi, Lanxiang Hao, Chunlei Wang, Ke Xu, Yanmei Liu, Xingbo Cheng · 2019 · Journal of Pharmacy and Pharmacology
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus
Bianca Hemmingsen, Jesper Krogh, Maria‐Inti Metzendorf, Bernd Richter · 2016 · Cochrane Database of Systematic Reviews
Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial
Bryony Beal, Luke Buizen, Emily K. Yeung, Lauren Heath, Lauren Houston, David Z.I. Cherney, Meg Jardine, Carol A. Pollock, Clare Gabrielle Arnott, Sradha S. Kotwal et al. · 2025 · Nephrology Dialysis Transplantation
Plant-derived Natural Products in Neurological and Psychiatric Disorders: Mechanisms of Action and Synergistic Roles with Probiotics
Mustafa M Shokr, Abdelghafar Mohamed Abu-Elsaoud, Seham M. Al Raish · 2026 · Molecular Neurobiology
Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
Nam Hoon Kim, Soo Kyung Lim, In‐Kyung Jeong, Eun‐Jung Rhee, Jun Sung Moon, Ohk‐Hyun Ryu, Hyuk‐Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim et al. · 2025 · Diabetes & Metabolism Journal
Managing noninsulin glucose-lowering medications before surgery: A comparison of clinical practice guidelines
Oscar L. Morey‐Vargas, Mona Gossmann, Jeffrey M. Ketz, Basem Abdelmalak · 2025 · Cleveland Clinic Journal of Medicine
Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial
Fumiaki Obata, Kenji Tani, Harutaka Yamaguchi, Ryo Tabata, Hiroyasu Bando, Issei Imoto · 2017 · The Journal of Medical Investigation
Sodium-Glucose Cotransporter-2 Inhibitors: Risks vs. Rewards When Caring for Older Adults
Erica Wilson, Aminah Jones, Nicole Brandt · 2022 · Journal of Gerontological Nursing
A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes
Afra Ishtiaque, Shahreen Mehmood Khan, Salman Azhar, Mehreen Mehmood, Saira Shahnawaz · 2022
In Vitro Cytotoxic, Genotoxic, Embryotoxic and Oxidative Damage Potentials by Empagliflozin
Kenan Çadırcı, Hasan Türkez, Özlem Özdemir Tozlu, Ömer Erkan Yapça, Muharrem Bayrak, Buğrahan Emsen, Adil Mardinoğlu · 2024 · Biology Bulletin
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects
Young‐Sim Choi, JaeJin Na, Seo Yeong Park, Jae Min Cho, Yoonhye Jeong, Jun Gi Hwang · 2025 · Clinical and Translational Science
Identification of New Small-Molecule SGLT2 Inhibitors: In-Silico Approach to Therapeutics for Diabetes-Related Complications
Ashanul Haque, Khalaf M. Alenezi, Md. Jahoor Alam, Safia Tazyeen · 2025 · ACS Omega
Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review
Sulthan Al Rashid, Arun Suriyan, Mohamed Bilal Azam, Rajkapoor Balasubramanian, Naina Mohamed Pakkir Maideen, Kumarappan Chidambaram, Palanisamy Amirthalingam · 2026 · Hormone and Metabolic Research
Effects of sodium-glucose cotransporter 2 inhibitors on body weight and metabolic parameters in obese patients with and without type 2 diabetes: a systematized narrative review
Djordje Baletic, Nataša Božić, M. Paut Kusturica, Ljiljana Tomić, Violeta Ilić Todorović, Sara Vasović, Aleksandar Rašković · 2026 · Current Medical Research and Opinion
Nutritional and Metabolic Management of the Diabetic Patient with Chronic Kidney Disease and Chronic Renal Failure
Mark E. Williams, Robert C. Stanton · 2012 · Elsevier eBooks
Inhibitory kotransportera glukozowo- -sodowego 2 (SGLT2): nowa grupa doustnych leków przeciwcukrzycowych
Blazej Przybyslawski, Piotr Karbowiak, Jacek Rzeszotarski, L Walasek · 2013 · Via Medica Journals
An Emerging Protagonist: Sodium Glucose Co-transporters (SGLTs) as a Burgeoning Target for the Treatment of Diabetes Mellitus
Danish Ahmed, Manju Sharma, Vikas Kumar, Pankaj S Yadav · 2012 · Journal of Diabetes & Metabolism
The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review
Hyder Osman Mirghani, Thomas Antony Thaniyath, Fakhralddin Abbas Elfakki · 2019 · Biology and Medicine
The Impact of SGLT2i Therapy on the Onset and Prognosis of Heart Failure in Patients with Type 2 Diabetes
Bogdan Timar, Adina Braha, Lucica Grigorică, Laura Gaiţă, Romulus Zorin Timar · 2020 · Timişoara Medical Journal
Pharmacological Treatments for Type 2 Diabetes
Roberto Pontarolo, Andria Cristina Conegero Sanches, Astrid Wiens, Helena Hiemisch Lobo Borba, Luana Lenzi, Suelem Tavares da Silva Penteado · 2013 · InTech eBooks
Dapagliflozin as add-on to Metformin; Network Meta-Analysis and Budget Impact Analysis
Edoardo Mannucci, Enrico Torre, Patrizia Berto · 2015 · Global & Regional Health Technology Assessment
Kidneys function in glucose homeostasis regulation and its therapeutic implications
Ewa Otto-Buczkowska, Krzysztof Tucholski · 2013 · Family Medicine & Primary Care Review
SGLT2 inhibitors: New medicines for addressing unmet therapeutic needs in type 2 diabetes
Robert Geoffrey Moses, Stephen Colagiuri, Carol A. Pollock · 2014 · Australasian Medical Journal
Long-term mono- or dual-combination empagliflozin treatment for adults with type 2 diabetes mellitus
Bernd Richter, Elizabeth Bandeira-Echtler, Maria‐Inti Metzendorf, Bianca Hemmingsen · 2018 · Cochrane Database of Systematic Reviews
Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure
Mayu Yazaki, Takeru Nabeta, Takayuki Inomata, Kenji Maemura, Takumi Ooki, Teppei Fujita, Yuichiro Iida, Yuki Ikeda, Shunsuke Ishii, Takashi Naruke et al. · 2019 · Circulation Reports
A translational viewpoint explaining its potential salutary effects
Anne E. de Leeuw, Rudolf A. de Boer · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy
Hormonal Actions and Interactions in Proximal Tubule Cells Associated with the Development of Chronic Kidney Disease
Akihiko Saito, Michihiro Hosojima, Hiroyoshi Sato · 2011 · InTech eBooks
Use of a sodium–glucose cotransporter 2 inhibitor in a patient with chronic kidney disease
Michelle Lam, Adrian Coleman · 2016 · Journal of Renal Nursing
Empaglifozin and the reduction of risk of death in a high cardiovascular risk population
Ítalo Cordeiro Moreira, Gabriel Pereira Bernardo, D'ávila Suyane Belém de Lima, Cecília Brenda Rocha Carneiro, Débora Laésia Saraiva Ribeiro, Mariana Carleial Feijó de Sá, Maria Jaionara de Macedo, Priscila Passos Campelo Moreira, Vanessa Lacerda Araújo, José Nunes de Alencar et al. · 2016 · International Archives of Medicine
ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS
Durgaprasad Mallappa Kabade, Anand Koppad, Ameet Vasanthrao Khatawkar, Savitri Durgaprasad Kabade, Afaq Ahmed · 2016 · Journal of Evidence Based Medicine and Healthcare
What Next After Metformin? Guidelines and Indian Context
Chandalia Hb · 2017 · Current Research in Diabetes & Obesity Journal
Equine Insulin Dysregulation and Laminitis: Developing a Framework for Testing Treatment and Preventive Strategies
Alexandra Meier · 2019 · Queensland University of Technology
Discordance between fasting plasma glucose and A1c in the diagnosis and management of diabetes
Veerasak Sarinnapakorn, Chaicharn Deerochanawong, Sathit Niramitmahapanya, Navaporn Napartivaumnuay, Thitinan Treesaranuwattana · 2021 · World Journal of Advanced Research and Reviews
Nutritional and metabolic management of the diabetic patient with chronic kidney disease and chronic renal failure
Mark E. Williams, Robert C. Stanton · 2021 · Elsevier eBooks
Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients
Rasha O. Abdelmoniem, Marwa S. Shaalan, M. Shawky, Walla M. lbrahim, Ayman Elbadawy · 2022 · The Egyptian Journal of Hospital Medicine
Time to completely eradicate diabetic nephropathy
Usama A. Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim · 2023 · Diabetic Nephropathy
Estudo do efeito cardioprotetor da Empagliflozina no infarto agudo do miocárdio em ratos Wistar com diabetes induzida por estreptozotocina
Bruno Durante da Silva · 2023
Metabolism of the Total Flavonoid Extract of Lithocarpus litseifolius (Hance) Chun in Rats
Yuqing Zhao, Yali Yuan, Shu Yan, Chongzhuang Tang, Yong Gan, Shiyan Guo, Xingxing Diao · 2025 · Biomedical Chromatography
Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits
Sanja Medenica, Vladimir Prelević, Nikola Zanković, Viviana Maggio, Manfredi Rizzo · 2026 · Expert Opinion on Drug Safety
Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations
Zi Wang, Yijin Wang, Wangning Shangguan, Tao Li · 2026 · Frontiers in Cardiovascular Medicine
Canagliflozin treatment of a horse with hyperinsulinemia, including pharmacokinetic analysis of different dosing protocols: a case report
Cecily Burbidge, Katelyn White, Kate Armstrong, Brielle V. Rosa · 2026 · Frontiers in Veterinary Science
Plantago ovata (Psyllium Husk) Ameliorates Streptozotocin-Induced Diabetes in Rats via Modulating Oxidative Stress and the Expression of PPAR-γ, Nrf2, and TNF-α
Sachin T Jose · 2026
A Thorough Analysis of Analytical Techniques for Determining Dapagliflozin and Teneligliptin Hydrobromide Hydrate in Single and Combination Dosage Forms
Kalyani Sanjaykumar Patil, Javesh K. Patil, J. K. Patil · 2026 · Asian Journal of Pharmaceutical Research
BindingDB Entry 50040597: Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
BindingDB · 2013 · UC San Diego
Cardiac Electrophysiological Impact of Sodium Glucose Cotransporter 2 Inhibitors: A Comprehensive Review
Vishnu Ashok, Ven Gee Lim, S.M. Zubair Rahim, Hardip Sandhu, Michael S. Dodd, G. André Ng, Derek W. Renshaw, Helen L. Maddock, Faizel Osman · 2026 · Circulation Arrhythmia and Electrophysiology